User login
Dr. Malcolm Mason of Cardiff University in Wales discusses his report that adding radiotherapy to androgen deprivation therapy for locally advanced prostate cancer produced a durable survival benefit compared with hormone therapy alone. Findings come from the final 10-year analysis of a phase III intergroup trial carried out by the U.K. Medical Research Council, the National Cancer Institute of Canada, and the Southwest Oncology Group.
Dr. Malcolm Mason of Cardiff University in Wales discusses his report that adding radiotherapy to androgen deprivation therapy for locally advanced prostate cancer produced a durable survival benefit compared with hormone therapy alone. Findings come from the final 10-year analysis of a phase III intergroup trial carried out by the U.K. Medical Research Council, the National Cancer Institute of Canada, and the Southwest Oncology Group.
Dr. Malcolm Mason of Cardiff University in Wales discusses his report that adding radiotherapy to androgen deprivation therapy for locally advanced prostate cancer produced a durable survival benefit compared with hormone therapy alone. Findings come from the final 10-year analysis of a phase III intergroup trial carried out by the U.K. Medical Research Council, the National Cancer Institute of Canada, and the Southwest Oncology Group.